NCT07266402Phase 3Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Study sponsor: Celldex Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants240Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source